Spring into STEM | Using Chemical Engineering to Help Children with Cancer | Virtual Lecture Series

[[{"fid":"7909","view_mode":"non_responsive","fields":{"format":"non_responsive","alignment":"","field_file_image_alt_text[und][0][value]":"Stefan Guldin profile photo","field_file_image_title_text[und][0][value]":"","field_caption_heading[und][0][title]":"","field_caption_heading[und][0][url]":"","field_caption[und][0][value]":"","field_float_left_right[und]":"left","field_file_image_decorative[und]":"0"},"type":"media","field_deltas":{"1":{"format":"non_responsive","alignment":"","field_file_image_alt_text[und][0][value]":"Stefan Guldin profile photo","field_file_image_title_text[und][0][value]":"","field_caption_heading[und][0][title]":"","field_caption_heading[und][0][url]":"","field_caption[und][0][value]":"","field_float_left_right[und]":"left","field_file_image_decorative[und]":"0"}},"attributes":{"height":"140","width":"140","class":"media-element file-non-responsive"}}]]Dr Stefan Guldin is an associate professor in Chemical Engineering and head of the Adaptive and Responsive Nanomaterials (AdReNa) group at University College London. In 2021, he was appointed as Deputy Head of Department (Enterprise). He studied Physics at Karlsruhe Institute of Technology (2003-05) and the Technical University of Munich (2005-08) and graduated with a PhD from the University of Cambridge in 2012. Subsequently, Stefan carried out postdoctoral research as a scholar of the German Academy of Sciences at before taking up his current position in 2015. His research interests include the study of material formation on the nanoscale by molecular self-assembly, creation of adaptive and responsive materials architectures and translation into real-world applications, ranging from chemical sensors and biomedical diagnostics to electrochemical devices and optical coatings. To date, he has published over 50 peer-reviewed articles as well as six conference proceedings, one book chapter and one book. Stefan is co-founder of the biomedical start-up Vesynta, which is devoted to the development of companion drug monitoring solutions for personalised medicine with currently 4 full-time employees.